BANNOCKBURN, Ill.--(BUSINESS WIRE)--
Baxalta Incorporated (NYSE: BXLT) announced today the pricing of its
previously announced secondary public offering of 37,573,040 shares of
its common stock at a price to the public of $39.50 per share. Baxalta
is not selling any shares and will not receive any proceeds from the
sale of the shares in the offering or the debt-for-equity exchange (as
described below). The offering is expected to close on February 2, 2016,
subject to customary closing conditions.
Baxter International Inc., Baxalta’s former parent company (“Baxter”),
has exchanged the shares of Baxalta common stock to be sold in the
offering for indebtedness of Baxter held by Chase Lincoln First
Commercial Corporation (“Chase Lincoln”), an affiliate of the
underwriter in the offering. Following the debt-for-equity exchange and
offering, Baxter’s retained ownership stake in Baxalta will be reduced
from approximately 19.4% to 13.9%. Chase Lincoln, as selling
shareholder, is selling these shares of Baxalta common stock to the
underwriter in connection with the public offering.
J.P. Morgan Securities LLC is acting as the sole underwriter for the
The offering is being made only by means of a prospectus. A copy of the
prospectus related to the offering may be obtained from: J.P. Morgan
Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717, or by calling toll-free at (866) 803-9204.
You may also obtain a copy of the prospectus, without charge, by
visiting the SEC’s website at http://www.sec.gov.
A registration statement on Form S-1 relating to these securities has
been filed with, and declared effective by, the Securities and Exchange
Commission. This press release shall not constitute an offer to sell or
the solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
Baxalta Incorporated (NYSE: BXLT) is a global biopharmaceutical company
developing, manufacturing and commercializing therapies for orphan
diseases and underserved conditions in hematology, oncology and
immunology. Launched in 2015 following its separation from Baxter,
Baxalta’s therapies are available in more than 100 countries.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160127006472/en/
Source: Baxalta Incorporated